Financial Services
Drugs Made In America Acquisition II Corp. Unit(DMIIU)
Live Price
Offline$10.12
+0.00% today
Window Change
+1.70%
Window
Sep 25, 2025 → Jun 22, 2026
- Market Cap
- $630.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 184 bars · Sep 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Drugs Made In America Acquisition II Corp. Unit (DMIIU) is a Financial Services stock with a market cap of $630.00M and listed on NASDAQ. The stock last traded around $10.12 and up 1.7% across the available one-year price window (Sep 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines DMIIU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +3.4% peer median
Operating Margin
Below sector median
0.0% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.
Benchmark Edge
DMIIU vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DMIIU
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DMIIU Max Drawdown
-1.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DMIIU and SPY.
Company Overview
Drugs Made In America Acquisition II Corp. Unit
NASDAQ Global Select
A SPAC (blank check company) incorporated in the Cayman Islands to pursue a business combination. The company aims to focus on pharmaceutical / drug sector targets to reduce U.S. reliance on global drug manufacturing. Each unit consists of one ordinary share and one right to receive one-tenth of a share upon completion of a qualifying business combination.
- Leadership
- Roger Bendelac
- IPO Date
- Sep 25, 2025
- Employees
- 2
- Street Address
- 1 East Broward Boulevard
- Mailing
- Fort Lauderdale, FL, 33301
- Region
- Fort Lauderdale, FL, US
- Reporting Currency
- USD
- Investor Line
- 954 870 3099
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- —
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.